



Canadian Agency for
Drugs and Technologies
in Health



COMPUS

Canadian Optimal Medication Prescribing and Utilization Service

IDENTIFYING AND PROMOTING OPTIMAL DRUG THERAPY

View detailed information on our
Proton Pump Inhibitor Project
including intervention tools
at www.cadth.ca

Email: compusinfo@cadth.ca

Phone: (613) 226-2553

Fax: (613) 226-5392

Disclaimer: The information in this document is intended to help health care decision-makers, patients, health care professionals, health systems leaders and policymakers make well-informed decisions and thereby improve the quality of health care services.

While CADTH has taken care in the preparation of the document to ensure that its contents are accurate, complete and up-to-date, CADTH does not make any guarantee to that effect. The information in this document should not be used as a substitute for the application of clinical judgement in respect of the care of a particular patient or other professional judgement in any decision making process nor is it intended to replace professional medical advice. CADTH is not responsible for any errors or omissions or injury, loss or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this document.

CADTH takes sole responsibility for the final form and content of this document. The statements, conclusions and views expressed herein do not necessarily represent the view of Health Canada or any Provincial or Territorial Government.

Production of this document is made possible through a financial contribution from Health Canada. Copyright © CADTH 2007. This document may be reproduced for non-commercial purposes only and provided appropriate credit is given to CADTH.

OBJECTIVE COMPARATIVE DRUG INFORMATION & EDUCATION

It's all in the detail!

RxFiles

ACADEMIC DETAILING PROGRAM

Just Released:

RxFiles Drug Comparison Charts (6th Edition)

Covers over 55 therapeutic topics.

Order online at www.rxfiles.ca

Email: regierl@rxfiles.ca

Phone: (306) 655-8505

Fax: (306) 655-7980

1/0 Saskatoon City Hospital

701 Queen Street

Saskatoon, SK S7K 0M7

SASKATCHEWAN'S ACADEMIC DETAILING PROGRAM



Five Key Decision Points in the Approach to Patients with Uninvestigated Dyspepsia (pain or discomfort in upper abdomen) ³

1. Are there other possible causes for the symptoms? Consider cardiac, hepatobiliary, medication-induced, lifestyle or dietary indiscretion
2. Is the patient >50yrs, or does the patient have alarm symptoms? Alarm features and increased age identify patients at higher risk of organic causes, including cancer and ulcers.
Alarm symptoms - **VBAD**⇒ (Vomiting, Bleeding/anemia, Abdominal mass/uninvestigated wt loss, Dysphagia) ⇒ warrant prompt investigation
3. Is the patient regularly using conventional NSAIDs (including ASA)? Stop therapy if possible
4. Is the dominant symptom heartburn or acid regurgitation, or both? If yes, these are reliable indicators of GERD (gastroesophageal reflux disease)
5. Is the patient infected with *Helicobacter pylori*? Considering this question last will assist in legitimate indications for *H.pylori* testing

GERD

- symptomatic response to antisecretory therapy with proton pump inhibitors (**PPI**) or H2 antagonists (**H2RA**) is generally considered to support the presumptive diagnosis of GERD.
- mild symptomatic GERD can often be managed with lifestyle and dietary modifications along with OTC antacids or H2RAs

PHARMACOLOGICAL CONSIDERATIONS

Initial therapy

- Standard dose PPI is more efficacious than H2RA¹; double dose PPI is generally no more efficacious than standard dose for initial therapy in erosive esophagitis¹

Reassess therapy at 4 wks

- if response STOP therapy. If recurrence, repeat original therapy
- if symptoms not resolved, →if not on a PPI, switch to a PPI X 4-8 weeks →if on a PPI give bid x 4-8 weeks or consider investigation; (Ensure PPI taken 15-30 minutes before am meal; or at hs if primarily nocturnal symptoms)
- if symptoms respond to 4-8weeks of therapy STOP therapy, if symptoms recur repeat original therapy

Long-term therapy

- REASSESS NEED FOR THERAPY “patients should earn the right to be on long-term therapy”
- Tailor the dose and frequency to control symptoms. Patients should be maintained on the lowest dose of therapy that was adequate to provide symptom relief.

On-Demand PPI after response to initial PPI

- patients who respond to initial PPI therapy, subsequent “on-demand” PPI is more efficacious than continuous H2RA, but less efficacious than standard dose PPI {in uninvestigated GERD}¹

STANDARD DOSES OF PPIs

There are **no clinically important differences** among standard doses of PPIs in treatment of symptomatic GERD, ENRD and esophagitis¹ Patient variation in response may be seen.

{Standard dose: Omeprazole, rabeprazole & esomeprazole 20mg od; lansoprazole 30mg od; pantoprazole 40mg od}.

PPIs are **not efficacious** in asthma associated with GERD, in improving laryngeal symptoms associated with reflux or improving chronic cough with or without GERD¹

PUD & H.pylori (Non-NSAID PUD)

- ≈90% of DU & 70% of GU may be *H.pylori* positive
- the standard of care for all patients with GU/DU is *H.pylori* testing and treating if positive
- smoking cessation improves ulcer healing rates and reduces ulcers not related to *H.pylori* infection

H.pylori TESTING – Noninvasive

- diagnostic testing for *H. pylori* should only be performed in pts suspected of having *H.pylori*-related conditions such as PUD and if treatment is intended. (test and treat strategy)

Urea Breath Test (UBT)

- should be used for routine diagnosis, unless endoscopy is indicated for another reason
- excellent sensitivity, specificity and ease of use
- to prevent false –ve results patients should be off antibiotics & bismuth for at least 4wks & off PPIs/H2RA for at least 1wk

Serology:

- appropriate if no access to UBT or endoscopy, higher rate of false positives results (≈20%)

Repeat H.pylori testing after H.pylori eradication

- for uncomplicated DU, confirmation of *H.pylori* eradication is not required unless symptoms persist
- serology cannot be used to determine cure from infections (IgG antibodies detectable after 6-12 months after eradication)

H.pylori Regimens (see *H.pylori* Chart; all PPIs equally effective)

- H.pylori* regimens 1-2-3 =1 week, 2 times a day, 3 drugs commonly used, but four drug regimens an option
- single and two drug regimens not recommended
- 7 & 10 regimens equally effective, but 14 day regimens more efficacious than 7 days regimens¹
- consider the following when selecting regimen: allergy history, recent metronidazole use or EtOH intake (avoid metronidazole), potential compliance issues (1-2-3 regimens, Hp-PAC[®]), DIs {See also RxFiles H. Pylori Eradication chart <http://www.rxfiles.ca/acrobat/CHT-Hpylori.pdf>}

PPI treatment after H.pylori eradication

- for uncomplicated duodenal ulcer, once HP has been eradicated, continued PPI use does not produce higher ulcer healing rates and is generally not indicated¹ {Note: PPI may be indicated for acute healing of gastric ulcer}

PUD & NSAIDs - Prevention

- NSAIDs are responsible for the majority of HP negative PUD
- routine concomitant antiulcer prophylaxis is not warranted for all pts taking NSAIDs; assess patient risk

Preventing NSAID Induced Ulcer in High Risk Patients ¹

- High Risk: age >60, hx of ulcers/UGIB, warfarin, steroids, 2x normal dose NSAID. Those with several risk factors are at highest risk for NSAID-induced GI toxicity (up to 9% @6 months)
- avoid NSAID if possible (use acetaminophen)
- if NSAID must be used, use lowest dose & shortest duration
- GI Prophylaxis →standard dose PPI (all PPIs, similar efficacy)¹ →misoprostol 200ug tid-qid \$38-49 (GI upset & diarrhea) {H2RAs are not recommended for GI prophylaxis in NSAID pts}

HP Eradication and NSAID Use

- H.pylori* & NSAID additive on the risk of PUD/UGIB
- Prior to initiating chronic NSAIDs or low dose ASA, experts recommend *H.pylori* testing & treating if positive. Those at greatest risk (hx of peptic ulcers, dyspepsia, steroids, and/or warfarin) most likely to benefit.

COXIBs:

- The GI sparing effect of COXIBs is compromised when used concurrently with low dose ASA, therefore the GI advantage of a COXIB especially at high-dose is lost. When a COXIB is used with warfarin concurrently, the risk is similar to NSAIDs.
- COXIB risks are dose dependent {e.g. cardiac, renal, gastric}
- COXIB vs {NSAID + PPI} appear to have similar efficacy in prevention and recurrence of ulcer/bleeding in patients with previous NSAID associated UGIB¹

TREATMENT OF NSAID INDUCED ULCER

- Discontinue NSAID, *H.pylori* test & treat if positive, treat like a non-NSAID ulcer {e.g. PPI or H2RA (x4wk in DU); (x8wk in GU)}
- Healing rates: standard dose PPI x4-8weeks is more efficacious than H2RA or misoprostol¹

IF NSAID MUST BE CONTINUED

- secondary prevention PPI more effective than H2RA, but similar efficacy to misoprostol 400-800ug/day^{endoscopic evidence 1}
- H.pylori* – ‘ve pts (ulcer bleeding history) on low dose ASA+PPI have lower risk of ulcer complications vs clopidogrel alone¹

COXIBs= Selective cyclooxygenase 2 inhibitors DI=drug interactions DU=duodenal ulcer ENRD=endoscopic negative reflux disease EtOH=alcohol GERD=gastroesophageal reflux disease GI=gastrointestinal GU=gastric ulcer *H.pylori*=*helicobacter pylori* H2RAs=2-receptor antagonist NSAIDs=nonsteroidal anti-inflammatory drugs OTC=over the counter PPI=proton pump inhibitor PUD=peptic ulcer disease UBT=urea breath test UGIB=upper GI bleed. {See also <http://www.rxfiles.ca/acrobat/CHT-AcidSuppression.pdf>}

References

1. Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease [Scientific report]. DRAFT. Ottawa: The Agency; 2006 Dec 6. [See also RxFiles NSAID/COXIB chart: <http://www.rxfiles.ca/acrobat/CHT-NSAID-Cox2.pdf>]
2. 2006 UpToDate® • www.uptodate.com
3. Veldhuyzen van Zanen SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of *Helicobacter pylori*. Canadian Dyspepsia Working Group. CMAJ 2000;162(12 Suppl):S3-S23.
4. e-therapeutics www.e-therapeutics.ca
5. Preventing NSAID-Induced Ulcers... Pharmacist's Letter/Prescriber's Letter 2002; 18(3):1830-6.
6. Armstrong A, Marshall JK, Chiba N et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults – update 2004. Can J Gastroenterol 2005;19(1):15-35.
7. Hunt RH, Fallone CA, Thomson, ABR. Canadian *Helicobacter pylori* Consensus Conference Update: Infections in Adults. Can J Gastroenterol 1999;13(3): 213-217.
8. Hunt R, Thomson ABR. Canadian *Helicobacter pylori* Consensus Conference. Can J Gastroenterol 1998;12(1):31-41.

Copyright © & Disclaimer information at www.RxFiles.ca - <http://www.rxfiles.ca/Copyright%20&20Disclaimer.html>

NSAID Ulcer Risk Factors (x=↑in odds ratio risk): ●hx ulcer complications x13.5 ●multiple NSAIDs x9 ●high dose NSAID x7 ●concomitant anticoagulant use x6.4 ●age≥70 x5.6 ●age ≥60 x3.1 ●concomitant steroids x2.2 ●heart disease x1.8